Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
- PMID: 8180020
- PMCID: PMC1968915
- DOI: 10.1038/bjc.1994.173
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
Abstract
The 5T4 oncofetal antigen is a 72 kDa glycoprotein defined by a monoclonal antibody raised against human placental trophoblast and is expressed in many different carcinomas but detected only at low levels in some normal epithelia. Immunohistochemical analysis of the patterns of expression in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumour cells and metastatic spread. The 5T4 antigen phenotype of 72 colorectal cancers has been compared with the clinical outcome of the patients in order to assess its relationship with prognosis. Forty per cent of tumours were 5T4 positive; the remainder were either unlabelled or exhibited stroma-associated labelling only. There was a significant correlation between 5T4 expression in the malignant cells and unfavourable course of disease (P < 0.001). The 5 year survival with 5T4-positive tumours was 22% compared with 75% for patients with 5T4-negative tumours; median survival was 24 versus > 90 months respectively. Stratified analysis showed that 5T4 antigen tumour positivity was acting independently of each of stage, site of tumour, age or sex. There were significant differences in survival for patients with Dukes' B and C stage carcinomas (P = 0.001 and P = 0.034). The results suggest that in colorectal cancer immunohistochemical assessment of 5T4 expression may be useful in identifying patients at high risk for tumour recurrence and for whom additional treatment strategies might be most appropriate.
Similar articles
-
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.Clin Cancer Res. 1997 Nov;3(11):1923-30. Clin Cancer Res. 1997. PMID: 9815581
-
5T4 oncofetal antigen in gastric carcinoma and its clinical significance.Eur J Gastroenterol Hepatol. 1998 Jun;10(6):479-84. doi: 10.1097/00042737-199806000-00008. Eur J Gastroenterol Hepatol. 1998. PMID: 9855063
-
5T4 oncofetal antigen expression in ovarian carcinoma.Int J Gynecol Cancer. 1995 Jul;5(4):269-274. doi: 10.1046/j.1525-1438.1995.05040269.x. Int J Gynecol Cancer. 1995. PMID: 11578488
-
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Cancer Immunol Immunother. 2017 Apr;66(4):415-426. doi: 10.1007/s00262-016-1917-3. Epub 2016 Oct 18. Cancer Immunol Immunother. 2017. PMID: 27757559 Free PMC article. Review.
-
Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.Future Oncol. 2012 Mar;8(3):231-7. doi: 10.2217/fon.12.7. Future Oncol. 2012. PMID: 22409460 Review.
Cited by
-
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.Front Immunol. 2023 Mar 7;14:1090533. doi: 10.3389/fimmu.2023.1090533. eCollection 2023. Front Immunol. 2023. PMID: 36960052 Free PMC article.
-
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Oncotarget. 2017 Jul 18;8(29):47474-47489. doi: 10.18632/oncotarget.17666. Oncotarget. 2017. PMID: 28537896 Free PMC article.
-
Immunotherapy regimens for metastatic colorectal carcinomas.Hum Vaccin Immunother. 2018 Feb 1;14(2):250-254. doi: 10.1080/21645515.2017.1397244. Epub 2017 Dec 6. Hum Vaccin Immunother. 2018. PMID: 29083978 Free PMC article. Review.
-
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.Cancer Immunol Immunother. 2011 Jun;60(6):829-37. doi: 10.1007/s00262-011-0993-7. Epub 2011 Mar 9. Cancer Immunol Immunother. 2011. PMID: 21387109 Free PMC article. Clinical Trial.
-
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.Cancer Immunol Immunother. 2003 Oct;52(10):638-42. doi: 10.1007/s00262-003-0402-y. Epub 2003 Jun 14. Cancer Immunol Immunother. 2003. PMID: 12811528 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical